NTLA Q1 2022 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M+74.6% YoY

Gross Profit

-$122M-1082.9% margin

Operating Income

-$144M-1282.0% margin

Net Income

-$147M-1305.3% margin

EPS (Diluted)

$-1.96

QoQ Revenue Growth

-12.5%

Cash Flow

Operating Cash Flow

-$80M

Free Cash Flow

-$126M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$249M

Stockholders' Equity

$954M

Cash & Equivalents

$133M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$6M	+74.6%
Gross Profit	-$122M	-$33M	-271.1%
Operating Income	-$144M	-$46M	-210.7%
Net Income	-$147M	-$46M	-217.9%